Top Markets
Coin of the day
Caladrius Biosciences, Inc. Caladrius Biosciences, Inc.

Caladrius Biosciences, Inc.

CLBS
Peringkat dalam Saham #33300
Caladrius Biosciences, Inc. operates as a clinical-stage biopharmaceutical... Caladrius Biosciences, Inc. operates as a clinical-stage biopharmaceutical company primarily engaged in the development and commercialization of cellular therapies. These therapies aim to either reverse various diseases or stimulate the regeneration of compromised tissue. The company's pipeline includes several key investigational therapies: HONEDRA, which has received the prestigious SAKIGAKE designation, is undergoing Phase II clinical trials as a potential treatment for critical limb ischemia; XOWNA is currently in Phase IIb trials targeting coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy, is being evaluated for chronic kidney disease in patients prior to requiring dialysis. Previously known as NeoStem, Inc., the firm adopted its current name, Caladrius Biosciences, Inc., in June 2015. Established in 1980, the company maintains its corporate headquarters in Basking Ridge, New Jersey.
Harga Saham
$0.4264
Terakhir disinkronkan: 2022-09-14
Kapitalisasi Pasar
$7.93M
Perubahan (1 hari)
-16.44%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan Caladrius Biosciences, Inc. (CLBS)

Kategori

Riwayat harga saham Caladrius Biosciences, Inc. (CLBS)
Harga penutupan tertinggi: $0.50 pada 2022-09-01

Harga penutupan terendah: $20.36 pada 2015-06-01
Riwayat harga saham Caladrius Biosciences, Inc. dari 2015 hingga 2026
Performa harga saham tahunan
Tahun Performa
2022 -43.51%
2021 -42.36%
2020 -36.52%
2019 -44.38%
2018 26.20%
2017 2.72%
2016 -70.04%
2015 0.00%
Harga saham perusahaan atau pesaing serupa
Perusahaan Harga saham Perubahan 1th% Negara
$508.64 29.49%
US
$973.48 48.89%
NL
$733.78 6.78%
CH
$1.07K -6.40%
KR
$254.79 13.07%
BE